Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

help s.a. - diclofenac (diclofenac sodium) - tablets gastro-resistant - 50mg

Европска Унија - Енглески - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

Европска Унија - Енглески - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

Европска Унија - Енглески - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

Европска Унија - Енглески - EMA (European Medicines Agency)

laboratoires smb s.a. - fenofibrate, pravastatin - dyslipidemias - lipid modifying agents - pravafenix is indicated for the treatment of high-coronary-heart-disease (chd)-risk adult patients with mixed dyslipidaemia characterised by high triglycerides and low hdl-cholesterol (c) levels whose ldl-c levels are adequately controlled while on a treatment with pravastatin-40-mg monotherapy.

Европска Унија - Енглески - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dyslipidemias - lipid modifying agents - cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase hdl c levels when ldl c levels are adequately controlled with the corresponding dose of simvastatin monotherapy.

Европска Унија - Енглески - EMA (European Medicines Agency)

sanofi winthrop industrie - alirocumab - dyslipidemias - lipid modifying agents - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular disease praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.for study results with respect to effects on ldl-c, cardiovascular events and populations studied see section 5.1.

Израел - Енглески - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 3 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Израел - Енглески - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 6 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Израел - Енглески - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 9 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.